

# Product Innovations Help The G-CSF Market Players Gain Competitive Advantages

*The Business Research Company's  
Granulocyte Colony Stimulating Factors  
Market 2021 – Opportunities And  
Strategies – Global Forecast To 2030*

LONDON, GREATER LONDON, UK,  
December 2, 2021 /EINPresswire.com/


-- Companies in the granulocyte colony stimulating factors market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing

skills and expertise with other companies. While companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, in or out-licensing deals, this trend has been increasing over recent years. For instance, in September 2020, Humanigen, Inc., a clinical stage biopharmaceutical company collaborated with Lonza and Catalent to expand manufacturing of COVID-19 therapeutic candidate Lenzilumab. Lenzilumab is the patented Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody with the potential to prevent and treat cytokine storm, which is believed to cause the acute respiratory distress syndrome in severe COVID-19 cases.

TBRC's holiday sale has begun with discounts on ALL market research reports! [Grab your deal now.](#)

The increasing demand for prophylaxis granulocyte colony-stimulating factor (G-CSF) is another key factor driving the growth of the [G-CSF market](#). The prophylaxis with G-CSF decreases the occurrence of febrile neutropenia (FN), allowing patients to receive and stay on myelosuppressive chemotherapy. The current use of G-CSF prophylaxis offers significant benefits including reducing incidents of febrile neutropenia by 3.3 million and cases of chemotherapy reduced dosage intensity by less than 85%, over the next 10 years. Therefore, the increasing demand for prophylaxis granulocyte colony-stimulating factor is expected to drive the

Global G-CSF (Granulocyte Colony Stimulating Factors) Market  
Forecast Market Size, 2020 – 2030, \$ Billion



Source: The Business Research Company

Granulocyte Colony Stimulating Factors Market 2021  
– Opportunities And Strategies – Global Forecast To  
2030

growth of the G-CSF market.

Read More On The Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report:  
<https://www.thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market>

The global G-CSF market size reached a value of nearly \$5.00 billion in 2020, having decreased at a compound annual growth rate (CAGR) of -5.3% since 2015, primarily due to high uptake of biosimilars in the EU and USA and COVID impact. The G-CSF market is expected to grow from \$5.00 billion in 2020 to \$5.72 billion in 2025 at a rate of 2.7%. The global G-CSF market is then expected to grow at a CAGR of 6.3% from 2025 and reach \$7.76 billion in 2030.

Major players covered in the global G-CSF market are Amgen Inc., Coherus Biosciences Inc., Sandoz (Novartis), Biocon/Mylan, Teva Pharmaceuticals Inc.

North America was the largest region in the global G-CSF market, accounting for 50.1% of the total in 2020. It was followed by Western Europe, and then the other regions. Going forward, the fastest-growing regions in the G-CSF market will be Middle East, and Eastern Europe, where growth will be at CAGRs of 25.9% and 11.7% respectively. These will be followed by South America, and Africa where the G-CSF markets are expected to grow at CAGRs of 8.6% and 5.0% respectively.

TBRC's global G-CSF market report is segmented by type into lenograstim (granocyte), filgrastim (neupogen, zarzio, nivestim, accofil), long acting (pegylated) filgrastim (pegfilgrastim, neulasta, pelmeg, ziextenco), lipegfilgrastim (lonquex), by application into oncological diseases, blood disorders, growth hormone deficiencies, chronic and autoimmune disorders, others, by product into tablet, capsule, others.

The pegfilgrastim market was the largest segment of the G-CSF market segmented by type, accounting for 77.6% of the total in 2020. Going forward, the filgrastim segment is expected to be the fastest growing segment in the granulocyte colony stimulating factors market segmented by type, at a CAGR of 5.7% during 2020-2025.

G-CSF (Granulocyte Colony Stimulating Factors) Market 2021 - By Type (Pegfilgrastim, Filgrastim, Lenograstim), By Application (Oncology, Blood Disorders, Chronic and Autoimmune Disorders), And By Region, Opportunities And Strategies – Global Forecast To 2030 is one of a series of new reports from The Business Research Company that provides G-CSF (granulocyte colony stimulating factors) market overview, forecast G-CSF (granulocyte colony stimulating factors) market size and growth for the whole market, G-CSF (granulocyte colony stimulating factors) market segments, and geographies, G-CSF (granulocyte colony stimulating factors) market trends, G-CSF (granulocyte colony stimulating factors) market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request For A Sample Of The Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=3930&type=smp>

Here Is A List Of Similar Reports By The Business Research Company:

Biosimilars Global Market Report 2021 - By Product (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins), By Types (Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases), COVID-19 Growth And Change

<https://www.thebusinessresearchcompany.com/report/biosimilars-market-global-report>

Oncology Biosimilars Global Market Report 2021 - By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), COVID-19 Growth And Change

<https://www.thebusinessresearchcompany.com/report/oncology-biosimilars-market-global-report>

Blood And Blood Components Global Market Report 2021 - By Product (Whole Blood, Blood Components), By End-Users (Hospitals, Ambulatory Surgical Centers), By Application (Anemia, Trauma & Surgery, Cancer Treatment, Bleeding Disorders), By Blood Components (Red Blood Cells, Platelets, Plasma, White Blood Cells), COVID-19 Growth And Change

<https://www.thebusinessresearchcompany.com/report/blood-and-blood-components-global-market-report>

Interested to know more about [The Business Research Company?](#)

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

Or get a quick glimpse of our services here:

[https://www.youtube.com/channel/UC24\\_fl0rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_fl0rV8cR5DxICpgmyFQ)

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

The Business Research Company

Email: [info@tbrc.info](mailto:info@tbrc.info)

Follow us on LinkedIn: <https://bit.ly/3b7850r>

Follow us on Twitter: <https://bit.ly/3b1rmjS>

Check out our Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

[info@tbrc.info](mailto:info@tbrc.info)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/557397771>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.